Organoids and Cancer Models
A special issue of Organoids (ISSN 2674-1172).
Deadline for manuscript submissions: 30 June 2024 | Viewed by 429
Special Issue Editor
2. Departments of Pathology and Urology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Interests: cell reprogramming; telomerase and telomeres; patient-derived models; cell therapies; living biobanks; viruses; cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Traditional cancer models, including cell lines and animal models, have been widely used but have seen limited applications in both basic and clinical cancer research. Patient-derived model systems are needed for modeling human diseases and precision medicine. Genomics-based precision oncology only helps 2–20% of patients with solid cancer, and as such, functional diagnostics and patient-derived models are needed for precision cancer biology. Induced pluripotent stem cells (iPS), organoids, and conditional reprogramming (CR) are currently used widely for patient-derived cell models for disease and precision medicine. Both organoids and CR technologies have been cited in two NCI programs, the PDMR (Patient-Derived Cancer Model Repository) and HCMI (Human Cancer Models Initiative), the latter of which will be distributed through the ATCC. These cells can be easily manipulated in vitro, and thus, these patient-derived cells could be used for next-generation disease models. In this Special Issue, we will focus on the applications of organoids and other reprogrammed cells in cancer modeling and drug discovery.
Prof. Dr. Xuefeng Liu
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Organoids is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- patient-derived cells
- organoids
- iPS (induced pluripotent stem cells)
- CRC (conditionally reprogrammed cells)
- air–liquid interface cultures
- circulating tumor cells
- cancer modeling
- drug discovery
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
